Firebrick Pharma Ltd Market Cap ($5.69 Million)
Market Cap & Net Worth: Firebrick Pharma Ltd (FRE)
Firebrick Pharma Ltd market cap. Firebrick Pharma Ltd (AU:FRE) has a market capitalization of $5.69 Million (AU$8.04 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28237 globally and #1436 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Firebrick Pharma Ltd's stock price AU$0.03 by its total outstanding shares 287198985 (287.20 Million). Also see FRE operating cash flow for how efficiently the company converts equity into cash flow.
Firebrick Pharma Ltd Market Cap History (2022–2026)
Firebrick Pharma Ltd market cap history from 2022 to 2026. Data shows change from $46.74 Million to $5.69 Million (-45.98% CAGR). Check FRE live share price for real-time trading data and today's change.
Firebrick Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Firebrick Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore FRE year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
36.71x
Firebrick Pharma Ltd's market cap is 36.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $46.74 Million | $4.12K | -$3.80 Million | 11333.33x | N/A |
| 2023 | $10.16 Million | $830.00 | -$6.80 Million | 12241.66x | N/A |
| 2024 | $12.60 Million | $14.52K | -$1.18 Million | 867.59x | N/A |
| 2025 | $10.77 Million | $293.42K | -$2.63 Million | 36.71x | N/A |
Competitor Companies of FRE by Market Capitalization
Companies near Firebrick Pharma Ltd in the global market cap rankings as of November 7, 2026. Also see Firebrick Pharma Ltd balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Firebrick Pharma Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #19 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #28 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1354.00 |
| #19 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #28 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $276.22 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $291.31 |
Market Capitalization of Firebrick Pharma Ltd (2022–2026)
Market capitalization of Firebrick Pharma Ltd from 2022 to today. Between 2022 and today, Firebrick Pharma Ltd's market cap moved from $46.74 Million to $ 5.69 Million, with a yearly change of -45.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$5.69 Million | -47.17% |
| 2025 | AU$10.77 Million | -14.52% |
| 2024 | AU$12.60 Million | +24.00% |
| 2023 | AU$10.16 Million | -78.26% |
| 2022 | AU$46.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Firebrick Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.69 Million USD |
| MoneyControl | $5.69 Million USD |
| MarketWatch | $5.69 Million USD |
| marketcap.company | $5.69 Million USD |
| Reuters | $5.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.